OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
The grant will help two new scientists establish labs at OMRF.
These findings will help scientists understand how to better diagnose and treat the disease.
A trio of new principal scientists have joined OMRF.
Bell joined OMRF’s Board of Directors in 1988.
While mechanisms of viruses are complex, the reasons behind their spread aren’t.